

Basic information

2021/2552(RSP)

RSP - Resolutions on topical subjects

Resolution on Commission Implementing Regulation (EU) 2021/52 of 22 January 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin

Subject

3.10.09 Plant health legislation, organic farming, agro-genetics in general

Procedure completed

Key players

European Parliament	Committee responsible	Rapporteur	Appointed
	ENVI Environment, Climate and Food Safety	ARENA Maria (S&D)	09/02/2021
		METZ Tilly (Greens/EFA)	09/02/2021
		HAZEKAMP Anja (The Left)	09/02/2021

Key events

Date	Event	Reference	Summary
10/03/2021	Results of vote in Parliament		
11/03/2021	Decision by Parliament	T9-0079/2021	Summary
11/03/2021	End of procedure in Parliament		

Technical information

Procedure reference	2021/2552(RSP)
Procedure type	RSP - Resolutions on topical subjects
Procedure subtype	Resolution on implementing act or powers
Legal basis	Rules of Procedure EP 115-p2-3
Stage reached in procedure	Procedure completed
Committee dossier	ENVI/9/05318

Documentation gateway

European Parliament

Document type	Committee	Reference	Date	Summary
Motion for a resolution		B9-0162/2021	09/03/2021	
Text adopted by Parliament, single reading		T9-0079/2021	11/03/2021	Summary
European Commission				
Document type		Reference	Date	Summary
Commission response to text adopted in plenary		SP(2021)261	12/07/2021	

Resolution on Commission Implementing Regulation (EU) 2021/52 of 22 January 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin

2021/2552(RSP) - 11/03/2021 - Text adopted by Parliament, single reading

The European Parliament adopted by 472 votes to 214, with 9 abstentions, a resolution objecting to the Commission Implementing Regulation (EU) 2021/52 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin.

The approval period of the active substance dimoxystrobin has once again been extended by one year by Implementing Regulation (EU) 2021/52, which extends the approval period to 31 January 2022.

Parliament considered that Implementing Regulation (EU) 2021/52 exceeds the implementing powers provided for in Regulation (EC) No 1107/2009 concerning the placing of plant protection products on the Market. It considered that the decision to extend the approval period of dimoxystrobin is not in line with the safety criteria laid down in Regulation (EC) No 1107/2009 and is based neither on evidence that that substance can be used safely, nor on a proven urgent need for that substance in food production in the Union.

The Commission is called on to:

- repeal Implementing Regulation (EU) 2021/52 and to submit a new draft to the committee, which takes into account the scientific evidence on the harmful properties of all the substances concerned, especially those of dimoxystrobin;
- present a proposal for non-renewal of dimoxystrobin in the next meeting of the Standing Committee on Plants, Animals, Food and Feed;
- communicate to Parliament the specific reasons why the assessment of the substances has been delayed for reasons beyond the control of the applicants, which specific endpoints are still under assessment, and why that assessment requires so much time to be conducted;
- present draft implementing regulations to extend the approval periods only of substances for which the current state of science is not expected to lead to a Commission proposal for non-renewal of the approval of the active substance concerned;
- withdraw the approvals for substances, if proof or reasonable doubts exist that they will not meet the safety criteria laid down in Regulation (EC) No 1107/2009.

Lastly, Member States should ensure the proper and timely reassessment of the approvals of the active substances for which they are the reporting Member States, and to ensure that the current delays are solved effectively as soon as possible.